1. Report Industry Investment Rating - Not provided in the given content 2. Core Viewpoints of the Report - The Hong Kong innovative drug sector's valuation has not reached its peak and is below the 50% quantile. The industry is in a high - prosperity stage with improving performance in innovative drugs and CXO [1][11] - The innovative drug industry is entering a recovery phase in 2025, driven by industry trends, policies, and events. BD licensing of Chinese innovative drugs overseas is booming, indicating international recognition [2] - The Hong Kong Innovative Drug ETF (513120.OF) has advantages such as good liquidity, high - purity composition, and convenient trading, making it a good investment tool [4] 3. Summary by Directory 3.1 Value Analysis - **Valuation Level**: The PE of the China Securities Hong Kong Innovative Drug Index on August 8, 2025, was 45.73, below the 50% quantile (47.42x), indicating that the valuation of the Hong Kong innovative drug sector has not reached its peak [9] - **Performance Improvement**: The performance of innovative drugs (Biotech + Pharma) and CXO is improving. After ten batches of centralized procurement, innovative drug varieties of Pharma companies are becoming the main growth force, and leading biotech companies' products are rapidly expanding. CXO's performance is also rebounding due to the high - prosperity of the innovative drug track [11][13] - **Representative Companies**: Companies like BeiGene, Kelun Botai, and others have strong R & D capabilities, rich pipelines, and successful international cooperation experiences [20][23] - **Comparison between H - shares and A - shares**: H - shares have a larger scale, higher revenue, more listed Biotech companies, and lower valuations than A - shares. The proportion of innovative drugs in H - shares is also higher [36][39] 3.2 Industry Analysis - **Development Stages**: From 2015 - 2025, the innovative drug industry has gone through preliminary exploration (2015 - 2018), capital boom (2019 - 2021), deep adjustment (2022 - 2024), and recovery (2025) stages [2] - **Policy Support**: Policies have evolved from governance system innovation to continuous optimization and national - level support. Domestic policies have accelerated the approval process and improved the commercialization of innovative drugs through measures like optimizing the review and approval process and promoting医保access [2][60] - **Ecosystem Features**: The 18A channel in Hong Kong provides financing for unprofitable biotech companies. Overseas cooperation has led to the re - evaluation of innovative drug companies' valuations, with increasing cooperation between Chinese and international pharmaceutical giants [76][80] - **Internationalization Potential**: China has achieved breakthroughs in the quantity, quality, and technology of innovative drugs. The number of self - developed innovative drugs ranks first globally, the proportion of FIC molecules ranks second, and the gap in drug listing time between China and foreign countries has been significantly shortened [88][90][92] 3.3 ETF Product Introduction - **ETF General Information**: The GF China Securities Hong Kong Innovative Drug ETF was established on July 1, 2022, tracking the China Securities Hong Kong Innovative Drug Index. It has good liquidity, with a fund scale of 16.76 billion yuan as of August 6, 2025, and its daily trading volume has increased significantly [99] - **Features and Advantages**: It has high - purity industry focus and concentration, with the weight of bioproducts and chemical pharmaceuticals in the index reaching 92.5%, and the top ten component stocks' concentration reaching 70.59%. The industry is in a period of intensive realization, and policies provide full - chain support [105][106] - **Configuration Attributes**: It is an efficient tool for investors to allocate to the Hong Kong Biotech track, helping to avoid individual stock R & D risks. It also has medium - to - long - term rotation allocation value, with the index's one - year return ranking first among QDII stock funds and significant south - bound capital inflows [107][108]

Core Insights - The Chinese innovative drug sector has gained global recognition, with the Hang Seng Medical ETF rising over 90% and the Hong Kong Stock Connect Innovative Drug Index increasing by 130% this year, indicating a shift to the first tier of global pharmaceutical capabilities [1] - There is a trend where investors are actively engaging in business development (BD) transactions rather than waiting for IPOs, with international capital looking to invest in domestic biopharmaceutical firms to explore promising drug development projects [1][2] - The investment model has evolved, focusing on direct investments in drug development projects and supply chain management, leading to opportunities for domestic general partners (GPs) to raise USD funds and enter international supply chains [1][2] Investment Trends - BD transactions have become mainstream in the industry, particularly large deals exceeding USD 1 billion related to overseas licensing of drug pipelines [2] - For instance, the collaboration between 3SBio and Pfizer involves a potential total transaction amount exceeding USD 6 billion, with an upfront payment of USD 1.25 billion [2] - The total value of BD transactions in the first half of the year surpassed USD 60 billion, highlighting the significance of this investment approach [2] Target Investment Institutions - International limited partners (LPs) are seeking three types of domestic GPs for investment in innovative drug projects: 1. GPs that invest in U.S. biopharmaceutical companies, primarily to introduce Chinese drug projects [3] 2. GPs that invest in foreign companies with Chinese drug authorizations [3] 3. GPs that lead investments in newly established domestic companies (NewCos) focused on overseas sales of Chinese drugs [3] NewCo as a Strategy - Establishing NewCos allows domestic GPs to enhance their bargaining power in international collaborations by determining their share of profits and selecting international teams for management [5][6] - NewCos can be established at a low valuation, enabling domestic GPs to leverage investments while providing accountability to domestic LPs [6] - However, the effectiveness of this model depends on the specific terms of agreements, particularly regarding profit-sharing and distribution [6] Challenges and Market Alignment - Despite the potential advantages of NewCos, challenges remain, particularly in aligning drug development with international market demands [7][8] - Domestic GPs need to better understand U.S. market needs and integrate into the drug project initiation phase to facilitate marketization and internationalization [8] - The use of AI technology is being explored to match Chinese drug projects with international buyer demands, enhancing the likelihood of successful collaborations [8][9] Investment Focus Areas - International LPs are also interested in investing in AI pharmaceutical companies, platforms that incubate multiple projects, and specific types of research and development projects [9] - The emphasis on supply chain management capabilities is crucial for the success of these investments, reflecting a shift in biopharmaceutical investment strategies [9]

Market Performance - The three major Hong Kong stock indices collectively rose, with the Hang Seng Index increasing by 1.65% to close at 25,270.07 points, the Hang Seng Tech Index rising by 1.52% to 5,543.17 points, and the Hang Seng China Enterprises Index up by 1.62% to 9,039.09 points[4][3]. Sector Performance - Among the ten sectors, all but utilities saw gains, with healthcare, information technology, and materials leading the way, rising by 8.02%, 4.95%, and 4.7% respectively[7][2]. - Conversely, utilities experienced a slight decline of 0.07%, while energy, finance, and industrial sectors had lower gains of 0.73%, 1.3%, and 1.38% respectively[7][2]. Liquidity and Trading Volume - The average daily trading volume on the Hong Kong Stock Exchange was HKD 256.86 billion, an increase of HKD 30.31 billion from the previous week[16][2]. - Short selling amounted to an average of HKD 29.12 billion, with the short selling ratio at 11.27%, down by 0.98 percentage points from the previous week[16][2]. Capital Inflows - Southbound capital saw a net inflow of HKD 38.12 billion, an increase of HKD 16.37 billion from the previous week, with a record single-day inflow of HKD 35.88 billion on August 15[16][2]. Valuation Metrics - As of August 15, the Hang Seng Index had a PE ratio of 11.52 and a PB ratio of 1.2, both up by 1.68% and 1.15% respectively from the previous week, placing them at the 85th percentile since 2019[21][2]. - The Hang Seng Tech Index's PE and PB ratios were 21.94 and 3.12, respectively, at the 23rd and 66th percentiles since 2019[21][2]. Economic Indicators - The U.S. 10-year Treasury yield rose by 6 basis points to 4.33%, while the risk premium for the Hang Seng Index was 4.35%, significantly below the 5% threshold since 2010[23][2]. - China's 10-year Treasury yield increased by 5.74 basis points to 1.7465%, resulting in a risk premium of 6.93% for the Hang Seng Index, at the 55th percentile since 2010[29][2]. Investment Outlook - Analysts recommend focusing on sectors with better-than-expected interim results, those benefiting from favorable policies, and high-dividend stocks for stable returns amid market uncertainties[44][2]. - Risks include uncertainties in domestic policy effectiveness, tariff policy disruptions, and geopolitical tensions[44][2].

Core Viewpoint - The A-share market has shown resilience and strength, with the Shanghai Composite Index rising over 20% in the past three months, reflecting the robustness of the Chinese economy [1][4]. Policy Factors - The recent rally in the A-share market is attributed to a combination of macroeconomic policies, including interest rate cuts, consumption and financial support measures, and various capital market reforms [2][3]. - The introduction of policies aimed at attracting medium to long-term capital into the market, such as public fund reforms and the reactivation of the fifth set of listing standards on the Sci-Tech Innovation Board, has created a synergistic effect with macroeconomic policies [2]. Financial Factors - The market has seen significant inflows from central stabilizing funds and insurance capital, which have been actively investing in high-dividend companies, enhancing the attractiveness of the stock market for investors [2]. - The decline in government bond yields and bank deposit rates has increased the willingness of institutions and individuals to invest in the stock market, contributing to a substantial influx of capital [2]. Economic Factors - The GDP growth rate of 5.3% in the first half of the year has provided a strong boost to the A-share market, alongside breakthroughs in AI technology and record-high overseas licensing of innovative drugs, leading to a revaluation of tech and pharmaceutical stocks [3]. - The temporary suspension of tariffs between China and the U.S. has positively influenced market sentiment, contributing to a more favorable environment for the A-share market [3]. Market Sentiment - The recent market recovery has led to increased discussions about the stock market, a rise in new retail investor accounts, and a general boost in market confidence, with analysts predicting a potential bull market [4]. - The central political bureau's emphasis on enhancing the attractiveness and inclusivity of the domestic capital market is seen as crucial for sustaining the upward trend in the A-share market [4]. Regulatory Considerations - Financial regulators are urged to maintain a steady market mechanism and respond promptly to external shocks while ensuring strict oversight to prevent market risks [5]. - Historical patterns of market behavior highlight the need for caution against speculative trading and the importance of a rational investment approach [5].

Group 1: Market Recognition and Performance - Chinese innovative drug assets are increasingly recognized globally, capturing a larger share of the global innovative drug licensing market [2] - In the first half of this year, Chinese A/H share listed innovative drug companies saw stock prices rise by 78%, significantly outperforming the healthcare sector and U.S. peers [2] - Chinese innovative drug licensing accounted for 27% of global transaction volume and 32% of global transaction value year-to-date [2] Group 2: IPO Trends and Market Dynamics - Multiple "10x stocks" have emerged in the Hong Kong pharmaceutical sector this year, with companies like Deqi Medicine and Hengrui Medicine seeing significant stock price increases [4][5] - At least 40 biopharmaceutical companies are currently waiting to go public in Hong Kong, indicating strong market interest [6] - The capital market's positive sentiment has led to several companies engaging in refinancing, with notable transactions from companies like Innovent Biologics and I-Mab [6] Group 3: Global Contribution and Challenges - One-third of the global clinical pipeline for innovative drugs comes from China, with Chinese companies capturing approximately 32% of global licensing transactions [7] - Despite the growth, only 10 out of 307 new drugs approved by the U.S. FDA since 2019 originated from China, highlighting the low global market share of Chinese innovative drugs [12] - Challenges remain, including the need for more robust clinical trial data and the impact of geopolitical factors on market access [13] Group 4: Focus Areas and Future Outlook - Oncology remains a primary focus for Chinese innovative drugs, accounting for over 60% of licensing transactions in the past three years [13] - The cardiovascular and metabolic (CVM) drug sectors are seeing increased interest, particularly in GLP-1 drugs, which are becoming a focal point for multinational companies [14] - The future success of Chinese GLP-1 drugs in global markets may depend on strategic partnerships with multinational corporations for licensing and distribution [14]

Market Overview - The market exhibited a volatile upward trend this week, with growth styles significantly outperforming value sectors, indicating an increase in trading activity and capital inflow willingness [1] - Major indices strengthened, led by technology growth sectors, reflecting heightened market attention on high-prosperity tracks [1][2] - A-share market saw the Shanghai Composite Index rise by 1.7% to 3696.77 points, marking a new weekly high since 2022, while the Shenzhen Component Index increased by 4.55% and the ChiNext Index surged by 8.84% [2] Sector Performance - In the A-share market, the communication sector rose by 7.66%, driven by surging AI computing demand, while the electronics sector increased by 7.02% due to a 20% year-on-year growth in global semiconductor sales [4] - The financial sector benefited from active market trading and policy expectations, contributing to the overall market's upward momentum [1] - In the Hong Kong market, healthcare, raw materials, and information technology sectors all saw gains exceeding 4%, with the healthcare sector specifically rising by 7.27% [4] Capital Flow and Market Sentiment - The capital market showed positive signals, with weekly trading volume and margin financing balances both surpassing recent highs, indicating strong support for the market [1] - The influx of incremental capital has enhanced market resilience, with the two financing balances exceeding 2 trillion yuan, reflecting renewed confidence in leveraged funds [6] Future Outlook - The A-share market is expected to maintain its strong momentum, with a continued upward trend anticipated, although caution is advised regarding potential profit-taking pressures at high levels [6] - The technology growth sector is projected to sustain high elasticity due to industry trends and policy support, particularly in AI computing infrastructure and semiconductor sectors [6] - Mid-term strategies should focus on AI computing, breakthroughs in new energy technologies, and innovative pharmaceuticals, while also considering defensive positions in traditional sectors [6]

Market Performance - As of August 15, the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index have increased by 10.29%, 11.71%, and 18.33% respectively this year, with the Shanghai Composite Index surpassing 3700 points, reaching a three-year high [1] - The total market capitalization of A-shares is 108.87 trillion yuan, with an increase of 15.11 trillion yuan year-to-date [1] Stock Performance - A total of 310 stocks have risen over 100% this year, excluding newly listed stocks, with over 50 stocks in the pharmaceutical and machinery sectors achieving this milestone [1][6] - The number of low-priced stocks (below 2 yuan) has decreased to 39, indicating a strong market trend [10][11] Industry Analysis - Among the 31 major industry sectors, most have seen positive growth, with non-ferrous metals, telecommunications, and pharmaceuticals leading with increases of 33.79%, 29.97%, and 23.58% respectively [3][4] - Only six sectors have experienced declines, with coal, food and beverage, and oil and petrochemicals showing the largest drops of 8.44%, 6.14%, and 2.34% respectively [3][4] Top Performing Stocks - The top ten stocks with the highest gains this year include companies like Shangwei New Materials, Shutaishen, and Changcheng Military Industry, with increases exceeding 340% [7][9] - Shangwei New Materials has seen the most significant rise, with a staggering increase of 1357.74%, growing its market capitalization from 2.686 billion yuan to 39 billion yuan [9] Low-Priced Stocks Overview - The 39 low-priced stocks are all from the main board, with the real estate sector having the highest number at 9 [11] - Among these low-priced stocks, 28 have a market capitalization below 10 billion yuan, and 25 reported losses in the first quarter of 2025 [11]

Market Performance - As of August 15, the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index have increased by 10.29%, 11.71%, and 18.33% respectively this year, with the Shanghai Composite Index surpassing 3700 points, reaching a three-year high [1] - The total market capitalization of A-shares is 108.87 trillion yuan, with an increase of 15.11 trillion yuan year-to-date [1] Stock Performance - A total of 310 stocks have risen over 100% this year, excluding newly listed stocks, with over 50 stocks in the pharmaceutical and machinery sectors achieving this milestone [1][4] - Among the 31 sectors tracked, most have seen gains, with non-ferrous metals, communications, and pharmaceuticals leading with increases of 33.79%, 29.97%, and 23.58% respectively [2][3] - Only six sectors have declined, with coal, food and beverage, and oil and petrochemicals experiencing the largest drops of 8.44%, 6.14%, and 2.34% respectively [2] Low-Priced Stocks - As of August 15, there are only 39 stocks with a closing price below 2 yuan, all of which are from the main board [7][8] - The real estate sector has the highest number of low-priced stocks at 9, followed by building decoration and basic chemicals with 4 each [8] - Among these low-priced stocks, 28 have a market capitalization below 10 billion yuan, and 25 reported losses in Q1 2025 [8] Top Performing Stocks - The top ten stocks with the highest gains this year include Shangwei New Materials, Shutaishen, and *ST Yushun, with increases exceeding 340% [5] - Shangwei New Materials has seen the largest increase of 1357.74%, with its market capitalization growing from 2.686 billion yuan to 39 billion yuan [5]

Core Insights - The A-share market has shown significant growth in 2023, with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index rising by 10.29%, 11.71%, and 18.33% respectively, reaching a three-year high above 3700 points [1] - A total of 310 stocks have increased by over 100% this year, with more than 50 stocks in the pharmaceutical and machinery sectors alone [1][6] - The total market capitalization of A-shares has increased by 15.11 trillion yuan, reaching 108.87 trillion yuan [1] Industry Performance - Among the 31 major industry sectors, most have experienced gains, with non-ferrous metals, telecommunications, and pharmaceuticals leading with increases of 33.79%, 29.97%, and 23.58% respectively [3] - Only six sectors have seen declines, with coal, food and beverage, and oil and petrochemicals experiencing the largest drops of 8.44%, 6.14%, and 2.34% respectively [3] Stock Performance - As of August 15, 2023, there are 4406 stocks with positive returns, accounting for over 80% of the total, with 1100 stocks rising by more than 50% and 310 stocks exceeding 100% [5] - The top ten stocks with the highest gains this year include companies like Shangwei New Materials and Shutaishen, with increases exceeding 340% [7][9] - The stock with the highest increase, Shangwei New Materials, has surged by 1357.74%, with its market capitalization growing from 2.686 billion yuan to 39 billion yuan [9] Low-Priced Stocks - The number of low-priced stocks (below 2 yuan) has decreased to 39, all of which are main board stocks [10][11] - The real estate sector has the highest number of low-priced stocks at 9, followed by construction decoration and basic chemicals with 4 each [11] - Among these low-priced stocks, 28 have a market capitalization below 10 billion yuan, and 25 reported losses in the first quarter of 2023 [11]

Core Viewpoint - The A-share market has seen a significant increase in financing balance, surpassing 2 trillion yuan, marking a ten-year high, indicating a robust market foundation and optimistic sentiment among investors [1][2][5]. Financing Balance Overview - As of August 15, the total financing balance in the A-share market reached over 2.04 trillion yuan, with the Shanghai Stock Exchange at approximately 1.04 trillion yuan and the Shenzhen Stock Exchange at about 1 trillion yuan [2]. - The financing balance has been on an upward trend since June, rising from around 1.8 trillion yuan to the current level [3]. - The last time the financing balance exceeded 2 trillion yuan was on July 1, 2015, when it reached 2.035 trillion yuan [2]. Market Dynamics - The recent market rally has been characterized by a broad-based increase, with over 4,600 stocks rising, and the Shanghai Composite Index surpassing 3,700 points [2]. - The number of investors participating in margin trading has also increased, reaching 547,700 on August 14, the highest since November 2024 [4]. Sector Performance - Key sectors driving the financing balance include electronics, non-bank financials, pharmaceuticals, and power equipment [4]. - The current market environment shows a more diversified allocation of financing compared to 2015, with a focus on growth sectors such as pharmaceuticals, electronics, and high-end manufacturing [6]. Investor Sentiment and Policy Impact - Analysts attribute the rise in financing balance to improved policy expectations and a recovery in market risk appetite, supported by regulatory signals aimed at stabilizing the capital market [5][6]. - The ongoing policies since September 2024 have contributed to a restoration of investor confidence, leading to increased trading volumes and new account openings [6]. Future Outlook - The optimistic sentiment suggests that the current market rally is not yet over, with expectations of continued high-level fluctuations in the market [7]. - Recommended sectors for investment include AI, innovative pharmaceuticals, military, and non-ferrous metals, which are expected to benefit from the current market dynamics [7].